Agios Appoints Jeffrey Capello to Board of Directors

3 years ago

– Board Member Paul Clancy Will Step Down at the End of His Term – CAMBRIDGE, Mass., April 19, 2023…

Tonix Pharmaceuticals Announces Presentations of Pre-Clinical Data on TNX-1700 in Syngeneic Models of Colorectal and Gastric Cancer at the American Association for Cancer Research Annual Meeting 2023

3 years ago

CHATHAM, N.J., April 19, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, today announced…

IGM Biosciences to Present at the Stifel 2023 Targeted Oncology Days

3 years ago

MOUNTAIN VIEW, Calif., April 19, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on…

C4 Therapeutics to Participate in the Stifel 2023 Virtual Targeted Oncology Days

3 years ago

WATERTOWN, Mass., April 19, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to…

Plus Therapeutics Completes Enrollment of the Original Three Patients Required for Cohort 8 of ReSPECT-GBM Phase 1/2a Trial

3 years ago

Presentation of data from ReSPECT-GBM Phase 1/2a and Phase 2b trials expected second half of 2023AUSTIN, Texas, April 19, 2023…

Celebrate 420 with Good Supply!

3 years ago

Enjoy a Blast of Summer Nostalgia with Good Supply’s New Product Lineup Now Available Across CanadaTORONTO, April 19, 2023 (GLOBE…

EvolveImmune Therapeutics Reports First Results from CRISPR-Cas9 T Cell Exhaustion Screening Platform at American Association for Cancer Research (AACR) Annual Meeting 2023

3 years ago

Novel Technology Identified Genes that Promote T Cell Exhaustion, and which are Unique from PD-1/PD-L1 Checkpoint Pathway Engineered CAR-T Cells…

SOLVE FSHD invests in Epic Bio for the development of a novel treatment for Facioscapulohumeral Muscular Dystrophy

3 years ago

Investment will further accelerate the development of EPI-321VANCOUVER, British Columbia, April 18, 2023 (GLOBE NEWSWIRE) -- SOLVE FSHD, a venture-philanthropic…

H1.co Named 2023 Website of the Year by the Health And IT Marketing Community

3 years ago

H1’s new brand strategy and website recognized by HITMC for its visual appeal and stellar contentNEW YORK, April 18, 2023…

Erasca Presents Promising Initial Phase 1b Dose Escalation Data from FLAGSHP-1 for ERAS-601 Plus Cetuximab in Patients with Advanced Solid Tumors at the 2023 AACR Annual Meeting

3 years ago

ERAS-601, a potential best-in-class SHP2 inhibitor, blocks oncogenic signal transduction to delay onset of therapeutic resistance Combination was well-tolerated; supports…